BRANDY ROSE: Open Payments
NPI 1669051751 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,360 in 63 payments from 12 companies in 2025. Trend: 2023 $692 · 2024 $734 · 2025 $1,360
Food & beverage: $1,360
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $313 |
| Janssen Pharmaceuticals, Inc | 5 | $188 |
| Vanda Pharmaceuticals Inc. | 9 | $159 |
| Hydrofera LLC | 1 | $147 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| Alkermes, Inc. | 6 | $123 |
| ABBVIE INC. | 4 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $69 |
| Reprise Biomedical, Inc. | 3 | $67 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
Products named: INGREZZA, INVEGA SUSTENNA, HYDROFERA BLUE, ARISTADA, REXULTI, HETLIOZ, VRAYLAR, FANAPT.
Industry payments across TN — which companies pay providers there.
